Democratic congressional report says Trump increased drugmaker holdings benefiting from Medicare exemptions
President Donald Trump's investments in pharmaceutical companies increased from a maximum of $1.7 million in 2024 to as much as $56.2 million by the end of 2025, according to a report released by Democrats on the Joint Economic Committee. The report highlights that the increase came after Trump returned to the White House and certain drugmakers in his portfolio benefited from Medicare exemptions.
